📊 Statistics
- Analyst 1 Year Price Target:
$2.89
- Upside/Downside from Analyst Target:
37.67%
- Broker Call:
15
- Dividend Minimum 3 Year Yield:
0.00%
- EPS Growth Range (1Y):
<0%
- Net Income Growth Range (1Y):
<0%
- Revenue Growth Range (1Y):
0-10%
-
Upcoming Earnings Date:
-
💰 Dividend History
Current year to date yield:
2.41%
📅 SGX Earnings Announcements for 8A8
8A8 (8A8)
Market: SGX |
Currency: SGD
Address:
📈 8A8 Historical Chart
🧾 Recent Financial Statement Analysis
March 16, 2026
China Medical System Holdings Limited (CMS) 2025 Annual Results: Financial Analysis & Investor Insights China Medical System Holdings Limited (CMS), dual-listed in Hong Kong and Singapore, released its audited consolidated annual results for the year ended 31 December 2025. The…
August 19, 2025
China Medical System Holdings Limited (CMS) Interim Results Analysis: H1 2025 China Medical System Holdings Limited (CMS), a Cayman Islands-incorporated pharmaceutical group, released its unaudited interim results for the six months ended 30 June 2025. The Group is listed on…
🔎 View more in SGX corporate News 🔎 View more in SGX Financial statements
📰 Related News & Research
Showing results matched by any of: 8A8, CMS, CHIH SP, CHINA HOLDINGS, CHINA MEDICAL SYSTEM
March 16, 2026
China Medical System Holdings Limited (CMS) 2025 Annual Results: Financial Analysis & Investor Insights China Medical System Holdings Limited (CMS), dual-listed in Hong Kong and Singapore, released its audited consolidated annual results for the year ended 31 December 2025. The…
March 14, 2026
China Medical System Announces NMPA Approval for Desidustat Tablets in China China Medical System Holdings: Desidustat Tablets Approved for Renal Anaemia in China Key Highlights Regulatory Milestone: On 13 March 2026, China Medical System Holdings Limited (CMS) announced that its…
March 5, 2026
China Medical System Holdings: Key Update on CMS-D008 Clinical Trials Approval China Medical System Holdings Limited: Major Business Update on CMS-D008 Clinical Trials Approval Key Highlights Investors Must Know Clinical Trial Approval for Innovative Obesity Drug: China Medical System Holdings…
March 5, 2026
China Medical System Holdings Announces Upcoming Board Meeting to Approve FY2025 Annual Results and Consider Final Dividend China Medical System Holdings Announces Board Meeting to Approve FY2025 Financial Results and Consider Final Dividend China Medical System Holdings Limited (the Company)…
February 24, 2026
China Medical System Announces Key Regulatory Milestone for Ruxolitinib Phosphate Cream in Atopic Dermatitis China Medical System's Dermavon Achieves Major Regulatory Milestone: Ruxolitinib Phosphate Cream NDA for Atopic Dermatitis Accepted and Granted Priority Review in China Key Highlights Regulatory Breakthrough:…
November 25, 2025
Broker Name: Maybank Investment Bank Berhad Date of Report: November 25, 2025 Excerpt from Maybank Investment Bank Berhad report. Report Summary Cahya Mata Sarawak (CMS) reported 3Q25 and 9M25 results that underperformed expectations, mainly due to higher-than-expected pre-operating costs in…
November 25, 2025
Broker Name: Maybank Investment Bank Berhad Date of Report: November 25, 2025 Excerpt from Maybank Investment Bank Berhad report. Report Summary: Cahya Mata Sarawak (CMS) reported 3Q25 and 9M25 earnings below expectations due to higher pre-operating costs in its phosphate…
August 19, 2025
China Medical System Holdings Limited (CMS) Interim Results Analysis: H1 2025 China Medical System Holdings Limited (CMS), a Cayman Islands-incorporated pharmaceutical group, released its unaudited interim results for the six months ended 30 June 2025. The Group is listed on…
June 29, 2025
Hong Kong-listed pharmaceutical group China Medical System (CMS) has filed for a secondary listing on the Singapore Exchange (SGX) mainboard, with trading expected to commence in July 2025. The move is part of CMS’s strategy to deepen its footprint in…
